Skip to main content
. 2021 Mar 25;11:6817. doi: 10.1038/s41598-021-86203-4

Table 3.

Univariate analysis of prognostic factors for lung cancer patients by age groups.

 ≤ 45  > 45 Total
Characteristic median survival month (95%CI) P value median survival month (95%CI) P value median survival month (95%CI) P value
Overall 23.0 (20.678,25.322) 27.0 (24.858,29.124) 26.0 (24.343,27.657) 0.001
Sex
Male 21.0 (17.616,24.384) 24.0 (21.679,26.321) 23.0 (21.215,24.785)
Female 25.0 (21.106,28.894) 0.002 38.0 (32.419,43.581)  < 0.001 32.0 (27.937,36.063)  < 0.001
Family history
Yes 20.0 (19.709,23.291) 28.0 (25.620,30.380) 25.0 (21.674,28.326)
No 25.0 (22.123,27.877) 0.012 31.0 (20.612,41.388) 0.408 26.0 (24.674,27.867) 0.284
Smoking
Yes 19.0 (15.699,22.301) 24.0 (21.685,26.315) 23.0 (21.262,24.738)
No 25.0 (21.507,28.493) 0.001 35.0 (30.038,39.692)  < 0.001 30.0 (26.724,33.276)  < 0.001
Drinking
Yes 21.0 (16.014,25.986) 26.0 (22.970,29.030) 24.0 (21.469,26.531)
No 25.0 (22.158,27.842 0.427 30.0 (26.424,33.576) 0.007 27.0 (24.826,29.174) 0.012
BMI
 < 24.0 23.0 (20.508,25.492) 26.0 (23.066,28.934) 25.0 (23.017,26.983)
 > 24.0 25.0 (20.931,29.069) 0.357 29.0 (25.952,32.048) 0.043 29.0 (26.198,31.802) 0.027
Symptoms at diagnosis
Yes 22.0 (19.686,24.314) 26.0 (23.945,28.055) 24.0 (22.599,25.401)
No 39.0 (17.972,60.028)  < 0.001 52.0 (41.754,62.246)  < 0.001 45.0 (38.106,51.894)  < 0.001
Site
Left 23.0 (18.733,27.267) 25.0 (22.571,27.429) 24.0 (22.013,25.987)
Right 25.0 (21.735,28.265) 0.443 31.0 (27.006,34.994) 0.004 28.0 (25.496,30.504) 0.007
Subside
upper lobe 33.0 (25.807,40.193) 43.0 (35.924,50.076) 41.0 (31.265,40.735)
Middle lobe 15.0 (4.024,25.976) 58.0 (44.756,71.244) 42.0 (22.468,37.532)
Low lobe 37.0 (24.367,49.633) 0.174 44.0 (35.745,52.255) 0.504 42.0 (35.683,52.317) 0.773
Cancer stage at diagnosis
I + II 63.0 (40.487,85.513) 79.0 (67.849,90.151)
III + IV 18.0 (215.569,20.341)  < 0.001 19.0 (17.529,20.471)  < 0.001 18.0 (16.769,19.231)  < 0.001
Pathology
SCLC 18.0 (12.791,23.209) 16.0 (13.669,18.331) 19.0 (16.391,21.609)
NSCLC 25.0 (22.218,27.782) 0.034 31.0 (28.398,33.602)  < 0.001 27.0 (25.030,28.970)  < 0.001
CEA
Normal 29.0 (23.543,34.457) 27.0 (23.208.30.792) 28.0 (24.507,31.493)
Abmormal 19.0 (16.680,21.320)  < 0.001 21.0 (18.709.23.231)  < 0.001 20.0 (18.406,21.549)  < 0.001
SCC
Normal 24.0 (20.467,27.533) 31.0 (27.388,34.612) 28.0 (25.076,30.924)
Abmormal 18.0 (8.368,27.632) 0.006 20.0 (12.242,27.758) 0.001 20.0 (15.424,24.576)  < 0.001
NSE
Normal 31.0 (23.192,38.808) 28.0 (24.052,31.948) 29.0 (25.321,32.679)
Abmormal 17.0 (13.805,20.195)  < 0.001 20.0 (16.390,23.610)  < 0.001 19.0 (16.707,21.293)  < 0.001
EGFR
Mutant 24.0 (8.882,39.118) 39.0 (16.171,61.829) 34.0 (26.573,41.427)
Not mutant 29.0 (21.958,36.042) 0.051 40.0 (30.651,49.349) 0.306 34.0 (20.139,47.861) 0.111
Surgery
Yes 60.0 (41.879,78.121) 69.0 (63.190,74.810) 69.0 (61.807,76.193)
No 18.0 (15.483,28.157)  < 0.001 18.0 (16.606,19.394)  < 0.001 18.0 (16.812,19.188)  < 0.001
Radiotherapy
Yes 23.0 (18.494,27.506) 33.0 (29.594,36.406) 30.0 (27.607,32.393)
No 24.0 (21.343,26.657) 0.213 20.0 (18.147,21.863)  < 0.001 21.0 (19.170,22.830)  < 0.001
Chemotherapy
Yes 23.0 (20.444,25.556) 31.0 (24.720,37.280) 29.0 (24.600,33.400)
No 23.0 (19.368,28.632) 0.497 27.0 (24.482,29.518) 0.222 26.0 (24.111,27.899) 0.094
Targeted therapy
Yes 24.0 (21.301,26.699) 28.0 (25.551,30.449) 27.0 (25.151,28.849)
No 21.0 (19.025,22.975) 0.474 26.0 (21.219,30.781) 0.436 23.0 (19.909,26.091) 0.207